Efficacy and safety of ciprofol for sedation/anesthesia in patients undergoing hysteroscopy: a prospective, randomized, non-inferiority trial

PMCID: PMC12180349

PMID: 40530830

DOI: 10.1080/07853890.2025.2517820

Journal: Annals of medicine

Publication Date: 2025-6-18

Authors: Cheng S, Wu H, Liu Z, Liu D, Cao M, et al.

Key Points

• Ciprofol demonstrated non-inferior anesthetic efficacy compared to propofol for hysteroscopy
• Injection pain was dramatically reduced in ciprofol group (1.613% vs. 41.935%)
• Ciprofol may provide a more physiologically stable anesthetic option, especially for patients with pre-existing medical conditions

Summary

This randomized clinical trial compared ciprofol, a novel short-acting anesthetic, with propofol for sedation during painless hysteroscopy. The study enrolled 124 women (62 per group) to evaluate the non-inferiority of ciprofol in terms of anesthetic efficacy and safety. While both drugs achieved a 100% hysteroscopy success rate, ciprofol demonstrated several notable advantages, including significantly lower injection pain (1.613% vs. 41.935%) and less respiratory and circulatory system impact.

The research revealed that ciprofol patients experienced higher diastolic blood pressure, oxygen saturation, and minute ventilation compared to the propofol group. Although ciprofol had slightly longer induction (approximately 5.6 seconds) and recovery times (approximately 1.5 minutes), these differences were considered clinically tolerable. The findings suggest ciprofol could be particularly beneficial for high-risk patients with underlying respiratory or cardiovascular conditions, offering a potentially safer alternative to traditional propofol sedation.